CAR T Cell Adds Scorpion Venom to Tackle Tumor Heterogeneity

A newly engineered CAR T cell that incorporates a peptide isolated from the venom of the deathstalker scorpion has broad brain tumor–binding capabilities that will be investigated in an upcoming clinical trial.

| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

ABOVE: A deathstalker scorpion
© ISTOCK.COM, LASTOVETSKIY

In chimeric antigen receptor T cell therapy, patients’ T cells are genetically engineered to recognize an antigen present on the surface of their tumors and destroy cancer cells. According to a study published on March 4 in Science Translational Medicine, a new CAR that incorporates chlorotoxin, a small peptide derived from scorpion venom, binds to a large proportion of brain tumor cells, despite the vast cellular heterogeneity of these cancers. The authors argue that this novel design could have therapeutic benefits for glioblastoma, an aggressive form of brain cancer that is notoriously difficult to treat, and have already opened a clinical trial to test their intervention.

The study is “of great significance to the CAR T cell immunotherapy field” because it “presents the development and implementation of a potentially ‘universal’ CAR for the treatment of [glioblastoma],” Luis Sanchez-Perez, a neurosurgeon and immunotherapy researcher at ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Amy Schleunes

    A former intern at The Scientist, Amy studied neurobiology at Cornell University and later earned her MFA in creative writing from the University of Iowa. She is a Los Angeles–based writer, editor, and communications strategist who collaborates on nonfiction books for Harper Collins and Houghton Mifflin Harcourt, and also teaches writing at Johns Hopkins University CTY. Her favorite projects involve sharing the insights of science and medicine.

Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
iStock

TaqMan Probe & Assays: Unveil What's Possible Together

Thermo Fisher Logo
Meet Aunty and Tackle Protein Stability Questions in Research and Development

Meet Aunty and Tackle Protein Stability Questions in Research and Development

Unchained Labs
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo

Products

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

iStock

Agilent BioTek Cytation C10 Confocal Imaging Reader

agilent technologies logo